LatestNewsPersonal Care & Hygiene

Ebola Cure Drugs Unveiled After Successful Trials


Two drugs that attack Ebola virus with antibodies, and neutralise the virus effects on human cells, have reportedly cured two infected Congolese. The drugs, REGN-EB3 and mAb114, though still undergoing trial, were administered to the 2 victims, at a treatment centre in Goma, eastern DR Congo.

The US National Institute of Allergies and Infectious Diseases (NIAID), which co-spored the trial of the drugs, admitted its effectiveness, compared to Zmapp and Remdesivir, two other drugs that were dismissed due to their ineffectiveness.

The Director of the institute, Dr. Anthony Fauci, said, the 2 new drugs  are the “first drugs that, in a scientifically sound study, have clearly shown a significant diminution in mortality”.

CobraReview gathered that the Ebola drugs were developed from antibodies harvested from the bodies of survivors. However, the drugs are only effective when administered to infected people on time. Currently, the rate of survival after using the drugs is 90%.

Ebola has been ravaging West Africa in the past 6 years. From the first confirmed case on March 24, 2014, close to 15,000 people have died in 6 countries, comprising Liberia, Dr Congo, Nigeria, Mali, Guinea, Nigeria and the US, from over 30, 000 cases.

Having passed the necessary trial and experimentation stages, it is expected that the drugs will be patented, manufactured on a massive scale, and subsidized for access as prescription drugs across victim countries.

CobraReview invites Readers, Product enthusiasts and consumers to send in their independent reviews of products/services and their experiences to for free and instant publication.

READ ALSO! MTN, Multichoice, Shoprite Asked To Quit Nigeria

READ ALSO! Prostate: What Many Men Don’t Know!

READ ALSO! Apple Set $1m Reward For Any Hacker Of Its iPhones, Macs

READ ALSO! CBN Rolls Out New Guidelines To Protect Depositors

READ ALSO! Engine Quality: Honda Orders Recall Of 222,674 Accord Sedans

READ ALSO! Disengaged Workers: Ecobank Paid Peanuts As Benefits To Loyal Staff

Like us on facebook

Follow us on twitter

Toyin Afilaka
Toyin Afilaka writes with simplicity and insight. He has a PR and brand marketing background. He has worked previously at MarketingMix, IGW Entertainment (Germany), and BrandFootPrint. He managed the MTN Project Fame between 2012 and 2015. Toyin loves travelling, writing, reading; and he treasures integrity.


    Leave a reply

    Your email address will not be published.

    You may also like

    More in Latest